Compare Cytokinetics Inc (CYTK) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Altria Group Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Altria Group Inc trades at $71.36 (market cap $119.25B). The key difference: Altria Group Inc is far larger — about 13.8× Cytokinetics Inc's market cap, and Altria Group Inc pays a 6.22% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Altria Group Inc for 154 Days on average.
| CYTK | MO | |
|---|---|---|
Market Cap | $8.62B | $119.25B |
Volume | 2,594,626 | 11,178,169 |
Sector | Health | Consumer Staples |
52-Week High | $87.26 | $74.92 |
52-Week Low | $54.76 | $54.72 |
Typical Hold Time | 19 Days | 154 Days |
Enterprise Value | $8.72B | $141.46B |
Dividend Yield | — | 6.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Altria Group (MO) trades at $69.39, up 1.22% today, with a bullish technical signal from moving averages. The stock shows strong profitability with a 39% net income margin and a 6.6% dividend yield, though recent earnings have been mixed with two misses in the last four quarters. Cash flow improved in 2025 with net cash flow of $1.33 billion, but the balance sheet carries negative equity of -$2.24 billion due to high liabilities.
The outlook is balanced: analyst consensus is bullish with a $69.71 price target, but risks include regulatory pressures on tobacco, declining margins, and high debt. The dividend appears sustainable from cash flow, yet negative equity and business shrinkage pose long-term concerns for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
